

## Bölüm 10

# NÖTROPENİK ATEŞ VE TEDAVİSİ

Okan BARDAKCI<sup>1</sup>  
Gökhan AKDUR<sup>2</sup>

### NÖTROPENİK ATEŞ

Nötropenik ateş acilde onkolojik hastalarda sık karşılaşılan durumlardan biridir. Kemoterapi alan hematolojik malignitelerde %80, solid tümörlerde ise %10-50 oranında görülmektedir (1).Nötropeni, kan nötrofil sayısının 1500 c/mm<sup>3</sup> altında olmasıdır. Ciddi nötropeni, sayının 500 c/mm<sup>3</sup>'ün altında olması veya 48 saat içinde 500 c/mm<sup>3</sup>'e düşmesinin beklenmesidir. Derin nötropeni ise bu sayının 100 c/mm<sup>3</sup>'ün altında olması olarak tanımlanır (2).

Nötropenik ateş, nötropenik bir hastada vücut ısısının bir kez 38.3 C° veya 1 saat süre ile 38.0 C° ölçüm olarak tanımlanır (3).

Kanser hastalarının etkin düzeyde aldığı sitotoksik antineoplastik tedaviler, bir taraftan miyelopoez sürecindeki üretimi baskımlarken, gastrointestinal mukozanın devamlılığını bozarak bakteri ve fungal kolonizasyon ile invaziv enfeksiyon riski oluşturur (4).

Fungal enfeksiyon riski ilk nötropenik ateş başvurusunda düşük olsa da, paranteral nutrisyon, ampirik antibiyotik kullanımı ve mukozit varlığı riski artırmaktadır (5).

Son yıllarda; katater kullanımının artması ile nötropenik hastalarda gram pozitif (staffilokok, streptokok) bakteriler, gram negatifler kadar ön plana çıkmaktadır (6).

Clostridium difficile ve gram negatif dirençli bakteri enfeksiyonlarının sıklığı

<sup>1</sup> Dr. Öğretim Üyesi Çanakkale Onsekiz Mart Üniversitesi Tıp Fakültesi Acil Tıp AD 1 Anabilim Dalı  
okanbardakci@comu.edu.tr

<sup>2</sup> Dr. Öğr. Üyesi Gökhan AKDUR Çanakkale Onsekiz Mart Üniversitesi Tıp Fakültesi Acil Tıp Anabilim Dalı  
oakdur@hotmail.com

## KAYNAKLAR

1. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. *Blood*. 2006;107(12):4628–35
2. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. *J Clin Oncol* 2018; 36:1443.
3. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2011;52(4):e56-93
4. Sickles, Edward A., William H. Greene, and Peter H. Wiernik. "Clinical presentation of infection in granulocytopenic patients." *Archives of Internal Medicine* 135.5 (1975): 715-719
5. Meidani M, Baniyasi M, Khorvash. Prevalence of fungemia in pediatric patients with febrile neutropenia. *Adv Biomed Res*. 2018;29(7):88
6. Morris PG, Hassan T, McNamara M, et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern. *Support Care Cancer*. 2008;16(9):1085–8
7. Bishop, KD, Castillo JJ. Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. *Leuk Lymphoma*. 2012;53(8):1617–9).
8. Moon JM, Chun BJ. Predicting the complicated neutropenic fever in the emergency department. *Emerg Med J*. 2009;26(11):802–6).
9. Perazzoli C, Feitosa MR, de Figueiredo-Pontes LL, da Rocha JJR, Simões BP, Féres O. Management of acute colorectal diseases in febrile neutropenic patients. *J Coloproctology*. 2014;34:189–92
10. Lee CC, Hsieh CC, Lee NY, et al. Different clinical presentation of community-onset bacteremia among neutropenic adults in the ED. *Am J Emerg Med*. 2015;33(7):907–12).
11. Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. *Cochrane Database Syst Rev*. 2013;29(6):CD003038).
12. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. *J Clin Oncol*. 2000;18(16):3038–51
13. Wood, Douglas E. "National Comprehensive Cancer Network (NCCN) clinical practice guidelines for lung cancer screening." *Thoracic surgery clinics* 25.2 (2015): 185-197
14. Infectious Diseases Society of Taiwan, Hematology Society of Taiwan, Medical Foundation in Memory Dr. Deh-Lin Cheng, et al. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. *J Microbiol Immunol Infect* 2005; 38:455.
15. Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. *Clin Infect Dis* 2004; 39 Suppl 1:S49.
16. Weissinger F, Auner HW, Bertz H, et al. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* 2012; 91:1161.
17. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2018. <http://www.nccn.org>

(Accessed on August 01, 2018).

18. Paesmans M, Klastersky J, Maertens J, et al. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? *Support Care Cancer* 2011; 19:1001.
19. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. *Infect Control Hosp Epidemiol* 2013; 34:1.
20. Satlin MJ, Calfee DP, Chen L, et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. *Leuk Lymphoma* 2013; 54:799.
21. Bow EJ. There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy. *J Antimicrob Chemother* 2013; 68:492.
22. Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications (20/10/2019 Tarihinde <https://www.uptodate.com/contents/treatment-and-prevention-of-neutropenic-fever-syndromes-in-adult-cancer-patients-at-low-risk-for-complications> ?search=treatment-and-prevention-of-neutropenic-fever-syndromes-in-adult-cancer-patients-at-low-risk-for-complications&source=searchresult&selectedTitle=1~150&usagetype=default&display\_rank=1 adresinden ulařılmıştır.)
23. Ha YE, Song JH, Kang WK, et al. Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy. *Support Care Cancer* 2011; 19:1761.
24. Tumbarello M, Trecarichi EM, Caira M, et al. Derivation and validation of a scoring system to identify patients with bacteremia and hematological malignancies at higher risk for mortality. *PLoS One* 2012; 7:e51612.
25. Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). *Clin Microbiol Infect* 2018; 24 Suppl 2:S53.
26. McKenzie H, Hayes L, White K, et al. Chemotherapy outpatients' unplanned presentations to hospital: a retrospective study. *Support Care Cancer* 2011; 19:963.
27. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. *J Clin Oncol* 2018; 36:3043.
28. Link H, Böhme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). *Ann Hematol* 2003; 82 Suppl 2:S105.
29. Bell MS, Scullen P, McParlan D, et al. Neutropenic sepsis guidelines. Northern Ireland Cancer Network, Belfast 2010. p. 1-11.
30. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. *Clin Infect Dis* 2011; 52:e56.
31. UpToDate(2019) Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients) (20/10/2019 Tarihinde [https://www.uptodate.com/contents/treatment-of-neutropenic-fever-syndromes-in-adults-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients-high-risk-patients?search=Prophylaxis%20of%20infection%20during%20chemotherapy-induced%20neutropenia%20in%20high-risk%20adults%27&topicRef=1153&source=see\\_link](https://www.uptodate.com/contents/treatment-of-neutropenic-fever-syndromes-in-adults-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients-high-risk-patients?search=Prophylaxis%20of%20infection%20during%20chemotherapy-induced%20neutropenia%20in%20high-risk%20adults%27&topicRef=1153&source=see_link) adresinden ulařılmıştır.
32. Sepkowitz KA. Treatment of patients with hematologic neoplasm, fever, and neutropenia. *Clin Infect Dis* 2005; 40 Suppl 4:S253.

33. Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. *Clin Infect Dis* 2005; 40 Suppl 4:S246.
34. Viscoli C, Castagnola E. Planned progressive antimicrobial therapy in neutropenic patients. *Br J Haematol* 1998; 102:879.
35. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. *Clin Infect Dis* 2005; 40 Suppl 4:S240.
36. Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. *Clin Infect Dis* 2005; 40 Suppl 4:S246.
37. Viscoli C, Castagnola E. Planned progressive antimicrobial therapy in neutropenic patients. *Br J Haematol* 1998; 102:879.
38. Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious d
39. Cornely OA, Wicke T, Seifert H, et al. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. *Int J Hematol* 2004; 79:74.
40. Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. *Ann Oncol* 2010; 21 Suppl 5:v252.iseases group trial XV. *J Clin Oncol* 2013; 31:1149.
41. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. *N Engl J Med* 1994; 330:1240.
42. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. *J Antimicrob Chemother* 2007; 59:5.
43. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. *Ann Intern Med* 2005; 142:979.
44. Madureira A, Bergeron A, Lacroix C, et al. Breakthrough invasive aspergillosis in allogeneic hematopoietic stem cell transplant recipients treated with caspofungin. *Int J Antimicrob Agents* 2007; 30:551.
45. Bow EJ. Point: fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients works for defined outcomes in defined populations, but must be used wisely. *J Natl Compr Canc Netw* 2004; 2:433.
46. Bow EJ. Prophylaxis. In: *Managing Infections in Patients with Hematological Malignancies*, Kleinberg M (Ed), Humana Press, 2009. p.259.
47. Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2013; 31:794.
48. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. *J Gastroenterol Hepatol* 2010; 25:864.
49. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. *Clin Infect Dis* 2011; 52:e56.
50. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2018. <http://www.nccn.org> (Accessed on May 25, 2018)
51. UpToDate (2019) Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults (20/10/2019 tarihinde [https://www.uptodate.com/contents/prophylaxis-of-infection-during-chemotherapy-induced-neutropenia-in-high-risk-adults?search=UPTODATE%20HIGH%20RISK%20NEUTROPENIC%20FEVER%20PROPHYLAXIS&source=search-result&selectedTitle=4~150&usage-type=default&display\\_rank=4](https://www.uptodate.com/contents/prophylaxis-of-infection-during-chemotherapy-induced-neutropenia-in-high-risk-adults?search=UPTODATE%20HIGH%20RISK%20NEUTROPENIC%20FEVER%20PROPHYLAXIS&source=search-result&selectedTitle=4~150&usage-type=default&display_rank=4) adresinden ulařılmıştır.

52. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant* 2009; 15:1143.
53. De Castro N, Neuville S, Sarfati C, et al. Occurrence of *Pneumocystis jiroveci* pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. *Bone Marrow Transplant* 2005; 36:879.
54. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant* 2009; 15:1143.
55. Stern A, Green H, Paul M, et al. Prophylaxis for *Pneumocystis pneumonia* (PCP) in non-HIV immunocompromised patients. *Cochrane Database Syst Rev* 2014; :CD005590.
56. Taplitz, Randy A., et al. "Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update." *J Clin Oncol* 36.30 (2018): 3043-54.
57. Lubel JS, Angus PW . Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. *J Gastroenterol Hepatol*. 2010;25(5):864.
58. Firpi RJ, Nelson DR. Viral hepatitis: manifestations and management strategy. *Hematology Am Soc Hematol Educ Program*. 2006.
59. Caira M, Candoni A, Verga L, et al .Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). *Haematologica*. 2015;100(2):284.